Featured Research

from universities, journals, and other organizations

Human Trial For Spinal Injury Treatment Launched By Purdue, Indiana University

Date:
December 4, 2000
Source:
Purdue University
Summary:
The first human clinical trial of a new treatment for spinal cord injuries was announced by the Purdue School of Veterinary Medicine and the Indiana University School of Medicine. Dogs suffering paralysis from natural causes regained partial function with the treatment.

INDIANAPOLIS – The first human clinical trial of a new treatment for spinal cord injuries was announced today (11/20) by the Purdue School of Veterinary Medicine and the Indiana University School of Medicine. The two institutions also reported that an Indianapolis donor has made a major commitment to support their joint paralysis research effort.

In a news conference at the Indianapolis Motor Speedway Trackside Media Center, the universities announced that the FDA-approved trial at IU is based on treatments developed at Purdue. Dogs suffering paralysis from natural causes regained partial function with the treatment.

In support of the effort, Mari Hulman George, chairman of the Indianapolis Motor Speedway, is contributing $2.7 million to Purdue and IU. The gift is being used to establish endowed professorships at both universities: a named professorship in the Purdue School of Veterinary Medicine's Institute for Applied Neurology and a named chair in the IU School of Medicine's Division of Neurosurgery.

"I am pleased to be able to help both Indiana and Purdue universities in their research to help victims of spinal cord injuries," said George. "In this season of Thanksgiving, perhaps this gift will help give more hope to those victims and their families who are looking forward to new developments. Our family has been touched by this, as have many. I very much appreciate what the state of Indiana is doing to help, and especially the efforts of Dr. Borgens and Dr. Nelson."

George's gift will augment funding from the state, which committed $1 million annually for two years to Indiana and Purdue universities to support the application of research on spinal cord and head injuries.

The human clinical trial will test whether weak electrical fields applied to spinal cord injuries can promote better functional recovery through regeneration of injured spinal cord nerve fibers. The electrical fields are imposed over the spinal cord injury through use of a new implantable medical device, called an extraspinal oscillating field stimulator.

The trial will begin later this year and is open to patients between the ages of 18 and 65 who have suffered a spinal cord injury. Patients must be entered into the trial within 18 days from the time of their injury; there are other exclusionary criteria that are available from the clinical trials coordinator.

Purdue Professor Richard Borgens, director of the Institute for Applied Neurology, said the state support coupled with George's contribution is helping speed the process of bringing promising experimental treatments into actual human clinical trials.

"In the past we have had to apply for grants and corporate sponsorships in order to fund human trials, and that process can take many years," he said. "Now we have been able, and will continue, to move more quickly into human trials with techniques found to be both safe and effective on animal patients."

Dr. Paul Nelson, Betsey Barton Professor and chairman of the neurosurgery division at IU, said the pairing of the two universities is unique. "This is the beginning of our research into treatments that can be used collectively to improve the regeneration of the injured human spinal cord," he said. "The IU-Purdue collaboration in spinal cord research is an important partnership. It fits the universities' drive to engage in translational research, which creates an effective bridge between basic science research and patient care."

Spinal cord injuries represent a growing medical and financial dilemma for state governments, yet only a few other states – Kentucky, Florida and Virginia among them – fund paralysis research.

The Indiana General Assembly approved the effort in spring 1999 and made the money available July 1999. The funds provide a stable operating budget for equipment and professional staff to conduct coordinated research and test new developments.


Story Source:

The above story is based on materials provided by Purdue University. Note: Materials may be edited for content and length.


Cite This Page:

Purdue University. "Human Trial For Spinal Injury Treatment Launched By Purdue, Indiana University." ScienceDaily. ScienceDaily, 4 December 2000. <www.sciencedaily.com/releases/2000/11/001122180201.htm>.
Purdue University. (2000, December 4). Human Trial For Spinal Injury Treatment Launched By Purdue, Indiana University. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2000/11/001122180201.htm
Purdue University. "Human Trial For Spinal Injury Treatment Launched By Purdue, Indiana University." ScienceDaily. www.sciencedaily.com/releases/2000/11/001122180201.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins